iNtRON Biotechnology KRX:048530KOSDAQ
인트론바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked14since Sep 11
In Q2 2026, iNtRON Biotechnology reported revenue of ₩2.0bn, up 66.0% year on year, and an operating loss of ₩1.6bn. iNtRON Biotechnology (인트론바이오) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 5 articles. The most common catalyst was contracts & orders (2). It was most often mentioned alongside 글로벌테크놀로지.
Filing signals 4 quarters of losses Screener
iNtRON Biotechnology quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.0bn | +66.0% | −₩1.6bn margin −80.4% | −₩2.3bn |
| Q1 2026 | ₩1.9bn | +58.7% | −₩2.2bn margin −115.0% | −₩2.3bn |
| Q4 2025 derived | ₩1.7bn | +12.0% | −₩2.0bn margin −119.8% | −₩4.1bn |
| Q3 2025 | ₩1.6bn | +34.3% | −₩2.1bn margin −127.3% | −₩1.7bn |
| Q2 2025 | ₩1.2bn | -31.0% | −₩2.0bn margin −159.5% | −₩1.1bn |
| Q1 2025 | ₩1.2bn | -37.9% | −₩1.8bn margin −155.0% | −₩2.0bn |
| Q4 2024 derived | ₩1.5bn | -59.1% | −₩1.3bn margin −88.1% | −₩1.5bn |
| Q3 2024 | ₩1.2bn | -27.7% | −₩1.6bn margin −135.1% | −₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
iNtRON Biotechnology top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest iNtRON Biotechnology news Korean headlines
-
인트론바이오, 유럽 바이오기업과 SC 플랫폼 ‘pHyal20’ MTA 체결
1 more on this story · 1 outlets
- 인트론바이오, 유럽 바이오기업과 SC 플랫폼 ‘pHyal20’ MTA 체결이데일리 · Oct 20 16:30
-
Major인트론바이오, 글로벌 빅파마와와 '차세대 피하주사 플랫폼' MTA 체결…"기술수출 논의 확대"
1 more on this story · 1 outlets
- 인트론바이오, 피하주사 플랫폼 ‘pHyal20’ 글로벌 제약사와 MTA 체결PRESS9 · Oct 20 10:29